...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urology >Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors.
【24h】

Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors.

机译：检测外周血细胞中的碳酸酐酶9基因表达可预测肾皮质肿瘤患者疾病复发的风险。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: To present extended follow-up on a cohort of patients with renal cortical tumors treated with partial or radical nephrectomy and preoperatively assess for carbonic anhydrase 9 tumor marker expression in the peripheral blood. METHODS: All patients were originally enrolled in an institutional review board-approved study assessing the role of a reverse-transcriptase polymerase chain reaction peripheral blood assay designed to detect the tumor-specific gene carbonic anhydrase-9 (CA9). A total of 41 patients with renal cortical tumors confined to the kidney were enrolled at a single institution and assessed preoperatively with peripheral blood test for CA9 expression before undergoing partial or radical nephrectomy. A Kaplan-Meier estimated survival analysis and log-rank test were performed to determine whether detection of peripheral blood cells expressing the CA9 gene influences disease-free and disease-specific survival. RESULTS: The median follow-up was 4.3 years. The median age was 71 years. Of the 41 patients, 26 were men and 15 were women. The estimated 5-year disease-free survival for patients with detectible expression of the CA9 gene in the peripheral blood was 39.5% compared with 88.1% for patients without detection of the CA9 gene (P = 0.048). On bivariate analysis, disease-free survival correlated with histologic type, tumor diameter, and tumor grade. CONCLUSIONS: The expression of the tumor-specific marker CA9 in the peripheral blood is associated with decreased disease-free survival in patients with renal cortical tumors. This is the first study reporting on the prognostic value of this peripheral blood-based tumor marker for kidney tumors.
机译：目的：对部分或根治性肾切除术治疗的肾皮质肿瘤患者进行广泛的随访，并术前评估其外周血中碳酸酐酶9肿瘤标志物的表达。方法：所有患者最初均参加了机构审查委员会批准的研究，评估一项旨在检测肿瘤特异性基因碳酸酐酶9（CA9）的逆转录酶聚合酶链反应外周血检测的作用。共有41名局限在肾脏内的肾皮质肿瘤患者被纳入一所机构，并在进行部分或根治性肾切除术前术前通过外周血测试评估CA9的表达。进行了Kaplan-Meier估计生存分析和对数秩检验，以确定检测表达CA9基因的外周血细胞是否影响无病生存和特定疾病生存。结果：中位随访时间为4.3年。中位年龄为71岁。在41名患者中，男性26名，女性15名。在外周血中可检测到CA9基因表达的患者的5年无病生存率估计为39.5％，而未检测到CA9基因的患者则为88.1％（P = 0.048）。在双变量分析中，无病生存与组织学类型，肿瘤直径和肿瘤等级相关。结论：肾皮质肿瘤患者外周血中肿瘤特异性标志物CA9的表达与无病生存期降低有关。这是第一项报道这种基于外周血的肿瘤标志物对肾脏肿瘤的预后价值的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号